The Dishman Group announces strategic alliance with Codexis
The Dishman Group announced the formation of a strategic alliance with Codexis, Inc. a California based biotechnology company. This strategic partnership covers the use of Codexis’ proprietary enzymatic biocatalysis technology for the manufacture of building blocks, intermediates and APIs for innovator pharmaceutical companies. Dishman will be a preferred contract manufacturer for Codexis and will be able to offer the technology to its own customers. In addition, the companies will work exclusively on certain select accounts.
“We are delighted to be working with Codexis on this innovative technology. It adds another dimension to the already extensive portfolio of services offered by the Dishman Group. Our customers will benefit from cheaper, cleaner, greener processes manufactured in a low cost environment, a significant differentiator given today’s regulatory and market conditions ” said Nick Green, President Dishman CRAMS.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Merck: Closure of the Geneva and Coinsins sites is confirmed - Merck Serono Announces Final Efficiency Program for Switzerland
Tom_Smith_(rugby_player)
A new way of taming ions can improve future health care
Researchers rapidly turn bacteria into biotech factories
Artificial leaf as mini-factory for drugs
Key factors identified for regeneration of brain tissue - Researchers demonstrate in a zebrafish model that two proteins prevent scar formation in the brain, thereby improving the ability of tissue to regenerate
Eurofins expands its footprint in Asia with the acquisition of Lab Frontier in South Korea
Researchers decipher modus operandi of potential Alzheimer’s drug
A relative from the Tianyuan Cave - Ancient DNA has revealed that humans living some 40,000 years ago in the area near Beijing were likely related to many present-day Asians and Native Americans
